Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: BTHCF, Forum) reported on Monday that it had received positive feedback from the US Food and Drug Administration regarding its plans to conduct a phase 2 COVID-19 clinical trial using its repurposed drug NP-120 (Ifenprodil).
To learn more,
click here.
This follows news from the clinical stage pharmaceutical development Company where Health Canada also gave positive feedback over its phase 2 COVID-19 clinical trial. AGN also recently reported that that a regulatory submission had been made to the Ministry of Food and Drug Safety in South Korea for an investigator-led COVID-19 study with
Ifenprodil.
FULL DISCLOSURE: Algernon Pharmaceuticals Inc. is a client of Stockhouse Publishing.